Filing Flows › Comparisons › CVSI vs CNTB
CV Sciences vs Connect Biopharma Holdings: CVSI and CNTB compared
CV Sciences is the larger company: $3.0M of revenue in its latest quarter (Q2 2026) against $2.8M for Connect Biopharma Holdings (Q2 2026). Connect Biopharma Holdings is growing faster (58× against -18% a year earlier). CV Sciences is more profitable, with an operating margin of -10.1% against -636.0%.
Where the money goes: CVSI and CNTB
CV Sciences (CVSI) · Q2 2026
CV Sciences, Q2 2026: revenue $3.0M (-18% year over year), operating margin -10.1%, net loss $775K, operating cash flow $20K. The chart follows the revenue to costs, profit and cash.
Connect Biopharma Holdings (CNTB) · Q2 2026
Connect Biopharma Holdings, Q2 2026: revenue $2.8M (58× year over year), operating margin -636.0%, net loss $17.3M, operating cash flow −$15.9M. The chart follows the revenue to costs, profit and cash.
| CV Sciences (CVSI) | Connect Biopharma Holdings (CNTB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $3.0M | $2.8M |
| Revenue growth, Y/Y | -18% | 58× |
| Operating margin | -10.1% | -636.0% |
| Net earnings | −$775K | −$17.3M |
| Net margin | -26.0% | -624.4% |
| Operating cash flow | $20K | −$15.9M |
| Free cash flow | $13K | — |
Questions
Which is bigger, CV Sciences or Connect Biopharma Holdings?
CV Sciences is the larger company: $3.0M of revenue in its latest quarter (Q2 2026) against $2.8M for Connect Biopharma Holdings (Q2 2026).
Is CV Sciences or Connect Biopharma Holdings growing faster?
Connect Biopharma Holdings is growing faster (58× against -18% a year earlier).
Which is more profitable, CV Sciences or Connect Biopharma Holdings?
CV Sciences is more profitable, with an operating margin of -10.1% against -636.0%.
More: CV Sciences earnings · how CV Sciences makes money · Connect Biopharma Holdings earnings · how Connect Biopharma Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.